Application of Cerebrospinal Fluid AT(N) Framework on the Diagnosis of AD and Related Cognitive Disorders in Chinese Han Population

References

• Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. J Neuropathol Exp Neurol. 2012;71(4):266–273. doi:10.1097/NEN.0b013e31824b211b22437338
   PubMed Web of Science ®Google Scholar
• McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of health and human services task force on Alzheimer’s Disease. Neurology. 1984;34(7):939–944. doi:10.1212/WNL.34.7.9396610841
   PubMed Web of Science ®Google Scholar
• Grundman M, Pontecorvo MJ, Salloway SP, et al. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord. 2013;27(1):4–15. doi:10.1097/WAD.0b013e318279d02a23203162
   PubMed Web of Science ®Google Scholar
• Wolk DA, Price JC, Madeira C, et al. Amyloid imaging in dementias with atypical presentation. Alzheimers Dement. 2012;8(5):389–398. doi:10.1016/j.jalz.2011.07.00322285638
   PubMed Web of Science ®Google Scholar
• Jack CR, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–562. doi:10.1016/j.jalz.2018.02.01829653606
   PubMed Web of Science ®Google Scholar
• Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66(3):382–389. doi:10.1001/archneurol.2008.59619273758
   PubMedGoogle Scholar
• Lewczuk P, Riederer P, O’Bryant SE, et al. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: an update of the consensus of the task force on biological markers in psychiatry of the world federation of societies of biological psychiatry. World J Biol Psychiatry. 2018;19(4):244–328. doi:10.1080/15622975.2017.137555629076399
   PubMed Web of Science ®Google Scholar
• Schoonenboom NS, Reesink FE, Verwey NA, et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology. 2012;78(1):47–54. doi:10.1212/WNL.0b013e31823ed0f022170879
   PubMed Web of Science ®Google Scholar
• Bjerke M, Engelborghs S. Cerebrospinal fluid biomarkers for early and differential Alzheimer’s disease diagnosis. J Alzheimers Dis. 2018;62(3):1199–1209. doi:10.3233/JAD-17068029562530
   PubMed Web of Science ®Google Scholar
• Kester MI, van der Vlies AE, Blankenstein MA, et al. CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Neurology. 2009;73(17):1353–1358. doi:10.1212/WNL.0b013e3181bd827119858456
   PubMed Web of Science ®Google Scholar
• Wolfsgruber S, Polcher A, Koppara A, et al. Cerebrospinal fluid biomarkers and clinical progression in patients with subjective cognitive decline and mild cognitive impairment. J Alzheimers Dis. 2017;58(3):939–950. doi:10.3233/JAD-16125228527210
   PubMed Web of Science ®Google Scholar
• Steenland K, Zhao L, Goldstein F, Cellar J, Lah J. Biomarkers for predicting cognitive decline in those with normal cognition. J Alzheimers Dis. 2014;40(3):587–594. doi:10.3233/JAD-2014-13134324496071
   PubMed Web of Science ®Google Scholar
• Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64(3):343–349. doi:10.1001/archneur.64.3.noc6012317210801
   PubMedGoogle Scholar
• Cummings J. The role of biomarkers in Alzheimer’s disease drug development. Adv Exp Med Biol. 2019;1118:29–61.30747416
   PubMed Web of Science ®Google Scholar
• Duits FH, Prins ND, Lemstra AW, et al. Diagnostic impact of CSF biomarkers for Alzheimer’s disease in a tertiary memory clinic. Alzheimers Dement. 2015;11(5):523–532. doi:10.1016/j.jalz.2014.05.175325156643
   PubMed Web of Science ®Google Scholar
• Mouton-Liger F, Wallon D, Troussière AC, et al. Impact of cerebro-spinal fluid biomarkers of Alzheimer’s disease in clinical practice: a multicentric study. J Neurol. 2014;261(1):144–151. doi:10.1007/s00415-013-7160-324162039
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. American Psychiatric Association: Washington; 1994.
   Google Scholar
• Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51(6):1546–1554. doi:10.1212/WNL.51.6.15469855500
   PubMed Web of Science ®Google Scholar
• Román GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43(2):250–260. doi:10.1212/WNL.43.2.2508094895
   PubMed Web of Science ®Google Scholar
• McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863–1872. doi:10.1212/01.wnl.0000187889.17253.b116237129
   PubMed Web of Science ®Google Scholar
• Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology. 2013;81(13):1159–1165. doi:10.1212/WNL.0b013e3182a55f1723966248
   PubMed Web of Science ®Google Scholar
• Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Movement Disord. 2017;32(6):853–864. doi:10.1002/mds.2698728467028
   PubMed Web of Science ®Google Scholar
• Hansen D, Ling H, Lashley T, et al. Novel clinicopathological characteristics differentiate dementia with Lewy bodies from Parkinson’s disease dementia. Neuropathol Appl Neurobiol. 2020.
   Web of Science ®Google Scholar
• Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303–308. doi:10.1001/archneur.56.3.30310190820
   PubMed Web of Science ®Google Scholar
• Van der Mussele S, Fransen E, Struyfs H, et al. Depression in mild cognitive impairment is associated with progression to Alzheimer’s disease: a longitudinal study. J Alzheimers Dis. 2014;42(4):1239–1250. doi:10.3233/JAD-14040525024328
   PubMed Web of Science ®Google Scholar
• Lim A, Tsuang D, Kukull W, et al. Clinico-neuropathological correlation of Alzheimer’s disease in a community-based case series. J Am Geriatr Soc. 1999;47(5):564–569. doi:10.1111/j.1532-5415.1999.tb02571.x10323650
   PubMed Web of Science ®Google Scholar
• Kester MI, Boelaarts L, Bouwman FH, et al. Diagnostic impact of CSF biomarkers in a local hospital memory clinic. Dement Geriatr Cogn Disord. 2010;29(6):491–497. doi:10.1159/00031353420523047
   PubMed Web of Science ®Google Scholar
• Falgàs N, Tort-Merino A, Balasa M, et al. Clinical applicability of diagnostic biomarkers in early-onset cognitive impairment. Eur J Neurol. 2019;26(8):1098–1104. doi:10.1111/ene.1394530793432
   PubMed Web of Science ®Google Scholar
• Somers C, Struyfs H, Goossens J, et al. A decade of cerebrospinal fluid biomarkers for Alzheimer’s disease in Belgium. J Alzheimers Dis. 2016;54(1):383–395. doi:10.3233/JAD-15109727567807
   PubMed Web of Science ®Google Scholar
• Niemantsverdriet E, Goossens J, Struyfs H, et al. Diagnostic impact of cerebrospinal fluid biomarker (pre-)analytical variability in Alzheimer’s disease. J Alzheimers Dis. 2016;51(1):97–106. doi:10.3233/JAD-15095326836187
   PubMed Web of Science ®Google Scholar
• Mulder C, Verwey NA, van der Flier WM, et al. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem. 2010;56(2):248–253. doi:10.1373/clinchem.2009.13051819833838
   PubMed Web of Science ®Google Scholar
• Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302(4):385–393. doi:10.1001/jama.2009.106419622817
   PubMed Web of Science ®Google Scholar
• Liu B, Tang Y, Shen Y, Cen L, Han M. Cerebrospinal fluid tau protein in differential diagnosis of Alzheimer’s disease and vascular dementia in Chinese population: a meta-analysis. Am J Alzheimers Dis Other Demen. 2014;29(2):116–122. doi:10.1177/153331751350737424164930
   PubMed Web of Science ®Google Scholar
• Shoji M, Matsubara E, Murakami T, et al. Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group. Neurobiol Aging. 2002;23(3):363–370. doi:10.1016/S0197-4580(01)00309-811959397
   PubMed Web of Science ®Google Scholar
• Ceccaldi M, Jonveaux T, Verger A, et al. Added value of (18)F-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: a naturalistic study. Alzheimers Dement. 2018;14(3):293–305. doi:10.1016/j.jalz.2017.09.00929107051
   PubMed Web of Science ®Google Scholar
• Sonnen JA, Postupna N, Larson EB, et al. Pathologic correlates of dementia in individuals with Lewy body disease. Brain Pathol. 2010;20(3):654–659. doi:10.1111/j.1750-3639.2009.00371.x20522091
   PubMed Web of Science ®Google Scholar
• Reesink FE, Lemstra AW, van Dijk KD, et al. CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer’s disease. J Alzheimers Dis. 2010;22(1):87–95. doi:10.3233/JAD-2010-10018620847452
   PubMed Web of Science ®Google Scholar
• Bellomo G, Paolini Paoletti F, Chipi E, et al. A/T/(N) profile in cerebrospinal fluid of Parkinson’s disease with/without cognitive impairment and dementia with lewy bodies. Diagnostics. 2020;10(12).
   Web of Science ®Google Scholar
• Bigio EH, Mishra M, Hatanpaa KJ, et al. TDP-43 pathology in primary progressive aphasia and frontotemporal dementia with pathologic Alzheimer disease. Acta Neuropathologica. 2010;120(1):43–54. doi:10.1007/s00401-010-0681-220361198
   PubMed Web of Science ®Google Scholar
• Josephs KA, Petersen RC, Knopman DS, et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology. 2006;66(1):41–48. doi:10.1212/01.wnl.0000191307.69661.c316401843
   PubMed Web of Science ®Google Scholar
• Le Bastard N, Martin JJ, Vanmechelen E, Vanderstichele H, De Deyn PP, Engelborghs S. Added diagnostic value of CSF biomarkers in differential dementia diagnosis. Neurobiol Aging. 2010;31(11):1867–1876. doi:10.1016/j.neurobiolaging.2008.10.01719150153
   PubMed Web of Science ®Google Scholar
• Biscetti L, Salvadori N, Farotti L, et al. The added value of Aβ42/Aβ40 in the CSF signature for routine diagnostics of Alzheimer’s disease. Clin Chim Acta. 2019;494:71–73. doi:10.1016/j.cca.2019.03.00130844364
   PubMed Web of Science ®Google Scholar